# Correlations between circulating adipokines and hepatocellular carcinoma: a Systematic Review and meta-analysis

**Authors:** Yani Ke, Yuyan Pan, Xueru Huang, Xing Bai, Xiaojuan Liu, Mingsi Zhang, Tao Jiang, Guangji Zhang

PMC · DOI: 10.3389/fendo.2025.1548924 · 2025-06-18

## TL;DR

This study finds that certain fat-related proteins in the blood are linked to liver cancer, suggesting they could help detect or predict the disease.

## Contribution

The study identifies specific adipokines as potential biomarkers for hepatocellular carcinoma and highlights the influence of viral hepatitis on these associations.

## Key findings

- HCC patients have significantly higher levels of adiponectin, leptin, visfatin, and resistin compared to controls.
- Circulating irisin levels are significantly lower in HCC patients.
- Visfatin shows good diagnostic value for HCC in clinical practice.

## Abstract

Hepatocellular carcinoma (HCC) is among the most common malignant tumors, characterized by high incidence and mortality rates. The role of adipokines in liver diseases is increasingly recognized and involves multiple contributing factors. Therefore, we summarized the relationship between circulating adipokines and HCC to guide directions for future research.

Six databases were searched, and all data were presented as standardized mean difference (SMD) or weighted mean difference (WMD). Sensitivity analysis and meta-regression were also performed. Diagnostic meta-analysis results were primarily presented using receiver operating characteristic (ROC) curves.

A total of 41 articles were included in this meta-analysis. HCC patients had significantly higher levels of circulating adiponectin, leptin, visfatin, and resistin compared to the controls (SMD = 1.6, 95% CI: 0.65-2.56; SMD = 2.45, 95% CI: 1.59-3.31; SMD = 2.49, 95% CI: 1.32-3.65; SMD = 4.17, 95% CI: 3.17-5.17, respectively). Conversely, circulating irisin levels in HCC patients were significantly lower than those in the control group (WMD = -1.16, 95% CI: -1.55, -0.77). Subgroup analysis identified possible sources of heterogeneity, whereas meta-regression confirmed that only the presence or absence of viral hepatitis was the source of high heterogeneity among leptin-related studies. Additionally, the meta-analysis results of diagnostic studies show that circulating visfatin demonstrates good diagnostic value for HCC, which may be helpful for clinical practice.

There is a significant association between circulating adipokines and HCC, and the presence of viral hepatitis is an influencing factor. Most adipokines are differentially expressed in HCC patients, and some may serve as biomarkers for early diagnosis or prognostic assessment.

https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023492972.

## Linked entities

- **Proteins:** lepa (leptin a), NAMPT (nicotinamide phosphoribosyltransferase), LOC114022543 (uncharacterized LOC114022543), FNDC5 (fibronectin type III domain containing 5)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), viral hepatitis (MONDO:0006011)

## Full-text entities

- **Genes:** RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, NAMPT (nicotinamide phosphoribosyltransferase) [NCBI Gene 10135] {aka 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}
- **Diseases:** viral hepatitis (MESH:D014777), HCC (MESH:D006528), malignant tumors (MESH:D009369), liver diseases (MESH:D008107)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12216435/full.md

---
Source: https://tomesphere.com/paper/PMC12216435